Sameer Awsare, MD, associate executive director for The Permanente Medical Group, shared in Biosimilars Development how Kaiser Permanente is a leader in the use of biosimilars.
Physician leader Sameer Awsare, MD, FACP, co-writes an article in Health Affairs encouraging competition in the biosimilar drugs market to help curb rising health care costs.
Presenting at this week’s GRx+Biosims meeting in North Bethesda, Maryland, Sameer Awsare, MD, associate executive director of The Permanente Medical Group, elaborated on how Kaiser Permanente leverages its integrated care model to drive collaboration in advancing the move to biosimilars.
During a public briefing at the Alliance for Health Policy, Sameer Awsare, MD, of The Permanente Medical Group, joined other health care leaders to explain the mechanisms of biosimilar drugs.